About
Katie Peng has served on Adicet Bio's board since July 2023. Since September 2021 she has been Chief Commercial Officer at Denali Therapeutics.
She previously served as Senior Vice President and Head of the Ophthalmology, Metabolism, Neurosciences and Immunology business unit at Genentech, and earlier held senior leadership positions at Roche managing the portfolio across the Asia Pacific region. She holds a B.A. from the University of California, Berkeley and an MBA from the Kelley School of Business, Indiana University.
Roles
Adicet Bio, Inc.
Director · Current role
2023–present
Genentech
SVP, Head of Ophthalmology, Metabolism, Neurosciences & Immunology Business Unit · Part of Genentech's commercial leadership team, responsible for the oncology, neurology and rare-diseases portfolio.
2017-2021
Roche Holding AG
General Manager / senior leadership, Asia Pacific · Managed the Roche portfolio in the Asia Pacific region as General Manager of two countries.
2012-2017
External Roles
Denali Therapeutics Inc.
Chief Commercial Officer
—
Scholar Rock Holding Corporation
Board member
—
California Life Sciences
Board member (non-profit)
—
Director Compensation
FY 2025Fees earned or paid in cash
$47,500
Stock awards
$4,630
Option awards
$15,715
Total
$67,845
Also at Adicet Bio, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.